Allianz Asset Management Gmb H Krystal Biotech, Inc. Transaction History

Allianz Asset Management Gmb H

$70.3 Billion
Q1 2025

A detailed history of Allianz Asset Management Gmb H transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 3,715 shares of KRYS stock, worth $505,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,715

Previous 4,102 9.43%

Holding current value

$505,537

Previous $642,000 4.21%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 05, 2025	SELL	$142.64 - $194.44 $55,201 - $75,248	-387 Reduced 9.43%	3,715 $669,000
Q4 2024 Feb 03, 2025	BUY	$156.64 - $199.61 $234,959 - $299,415	1,500 Added 57.65%	4,102 $642,000
Q3 2024 Nov 12, 2024	SELL	$174.7 - $213.66 $246,326 - $301,260	-1,410 Reduced 35.14%	2,602 $473,000
Q2 2024 Aug 13, 2024	SELL	$153.12 - $183.64 $83,603 - $100,267	-546 Reduced 11.98%	4,012 $736,000
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $17,065 - $28,337	158 Added 3.59%	4,558 $811,000
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $217,020 - $260,440	-2,000 Reduced 31.25%	4,400 $510,000
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $94,176 - $156,384	-1,200 Reduced 15.79%	6,400 $751,000
Q1 2023 May 11, 2023	SELL	$72.39 - $84.27 $347,472 - $404,496	-4,800 Reduced 38.71%	7,600 $608,000
Q4 2022 Feb 13, 2023	SELL	$63.14 - $79.9 $3,157 - $3,995	-50 Reduced 0.4%	12,400 $982,000
Q3 2022 Nov 08, 2022	SELL	$64.85 - $82.4 $2.93 Million - $3.73 Million	-45,239 Reduced 78.42%	12,450 $867,000
Q2 2022 Aug 12, 2022	BUY	$48.93 - $73.47 $1.36 Million - $2.04 Million	27,809 Added 93.07%	57,689 $3.79 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $453,404 - $628,871	8,721 Added 41.22%	29,880 $1.99 Million
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $842,339 - $1.87 Million	21,159 New	21,159 $1.48 Million
Q3 2021 Nov 10, 2021	SELL	$52.01 - $71.77 $408,746 - $564,040	-7,859 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $372 - $490	6 Added 0.08%	7,859 $534,000
Q1 2021 May 13, 2021	SELL	$59.42 - $85.46 $6,298 - $9,058	-106 Reduced 1.33%	7,853 $605,000
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $1,910 - $2,884	-47 Reduced 0.59%	7,959 $478,000
Q3 2020 Nov 13, 2020	SELL	$37.76 - $48.49 $26,394 - $33,894	-699 Reduced 8.03%	8,006 $344,000
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $479,427 - $776,820	-12,947 Reduced 59.8%	8,705 $361,000
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $335,596 - $629,028	-9,583 Reduced 30.68%	21,652 $937,000
Q4 2019 Feb 13, 2020	BUY	$33.17 - $65.23 $191,026 - $375,659	5,759 Added 22.61%	31,235 $1.73 Million
Q3 2019 Nov 13, 2019	BUY	$34.72 - $51.3 $3,298 - $4,873	95 Added 0.37%	25,476 $891,000
Q2 2019 Aug 08, 2019	SELL	$27.2 - $41.2 $268,572 - $406,808	-9,874 Reduced 28.01%	25,381 $1.02 Million
Q1 2019 May 13, 2019	BUY	$19.86 - $32.9 $700,164 - $1.16 Million	35,255 New	35,255 $1.16 Million

Others Institutions Holding KRYS

# of Institutions

328

Shares Held

24.3M

Call Options Held

299K

Put Options Held

97.6K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.49B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.

Account

Allianz Asset Management Gmb H Krystal Biotech, Inc. Transaction History